BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Al-Sukhni M, Maruschak NA, McIntyre RS. Vortioxetine : a review of efficacy, safety and tolerability with a focus on cognitive symptoms in major depressive disorder. Expert Opin Drug Saf 2015;14:1291-304. [PMID: 26022537 DOI: 10.1517/14740338.2015.1046836] [Cited by in Crossref: 35] [Cited by in F6Publishing: 25] [Article Influence: 5.8] [Reference Citation Analysis]
Number Citing Articles
1 Mandelli L, Serretti A, Porcelli S, Souery D, Mendlewicz J, Kasper S, Montgomery S, Zohar J. Opinion paper: poor response to treatment of depression in people in high occupational levels. Psychol Med 2019;49:49-54. [PMID: 30311597 DOI: 10.1017/S003329171800288X] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
2 Grant JE, Valle S, Cavic E, Redden SA, Chamberlain SR. A double-blind, placebo-controlled study of vortioxetine in the treatment of binge-eating disorder. Int J Eat Disord 2019;52:786-94. [PMID: 30938842 DOI: 10.1002/eat.23078] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
3 Orsolini L, Tomasetti C, Valchera A, Iasevoli F, Buonaguro EF, Vellante F, Fornaro M, Fiengo A, Mazza M, Vecchiotti R, Perna G, de Bartolomeis A, Martinotti G, Di Giannantonio M, De Berardis D. New advances in the treatment of generalized anxiety disorder: the multimodal antidepressant vortioxetine. Expert Rev Neurother 2016;16:483-95. [PMID: 27050932 DOI: 10.1586/14737175.2016.1173545] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
4 Baune BT, Sampson E, Louise J, Hori H, Schubert KO, Clark SR, Mills NT, Fourrier C. No evidence for clinical efficacy of adjunctive celecoxib with vortioxetine in the treatment of depression: A 6-week double-blind placebo controlled randomized trial. Eur Neuropsychopharmacol 2021;53:34-46. [PMID: 34375789 DOI: 10.1016/j.euroneuro.2021.07.092] [Reference Citation Analysis]
5 Salagre E, Grande I, Solé B, Sanchez-Moreno J, Vieta E. Vortioxetine: A new alternative for the treatment of major depressive disorder. Rev Psiquiatr Salud Ment (Engl Ed) 2018;11:48-59. [PMID: 28800937 DOI: 10.1016/j.rpsm.2017.06.006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
6 Salagre E, Solé B, Tomioka Y, Fernandes BS, Hidalgo-Mazzei D, Garriga M, Jimenez E, Sanchez-Moreno J, Vieta E, Grande I. Treatment of neurocognitive symptoms in unipolar depression: A systematic review and future perspectives. J Affect Disord 2017;221:205-21. [PMID: 28651185 DOI: 10.1016/j.jad.2017.06.034] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 8.3] [Reference Citation Analysis]
7 Ignácio ZM, da Silva RS, Plissari ME, Quevedo J, Réus GZ. Physical Exercise and Neuroinflammation in Major Depressive Disorder. Mol Neurobiol 2019;56:8323-35. [DOI: 10.1007/s12035-019-01670-1] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 14.0] [Reference Citation Analysis]
8 Anderzhanova E, Kirmeier T, Wotjak CT. Animal models in psychiatric research: The RDoC system as a new framework for endophenotype-oriented translational neuroscience. Neurobiol Stress 2017;7:47-56. [PMID: 28377991 DOI: 10.1016/j.ynstr.2017.03.003] [Cited by in Crossref: 56] [Cited by in F6Publishing: 43] [Article Influence: 14.0] [Reference Citation Analysis]
9 McIntyre RS, Lee Y, Mansur RB. Treating to target in major depressive disorder: response to remission to functional recovery. CNS Spectr 2015;20 Suppl 1:20-30; quiz 31. [PMID: 26683526 DOI: 10.1017/S1092852915000826] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 4.2] [Reference Citation Analysis]
10 Zimmerman M, Clark HL, Multach MD, Walsh E, Rosenstein LK, Gazarian D. Inclusion/exclusion criteria in placebo-controlled studies of vortioxetine: Comparison to other antidepressants and implications for product labeling. J Affect Disord 2016;190:357-61. [PMID: 26546771 DOI: 10.1016/j.jad.2015.10.041] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 Frampton JE. Vortioxetine: A Review in Cognitive Dysfunction in Depression. Drugs 2016;76:1675-82. [DOI: 10.1007/s40265-016-0655-3] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 6.8] [Reference Citation Analysis]
12 McIntyre RS, Lee Y. Cognition in major depressive disorder: a 'Systemically Important Functional Index' (SIFI). Curr Opin Psychiatry 2016;29:48-55. [PMID: 26575300 DOI: 10.1097/YCO.0000000000000221] [Cited by in Crossref: 47] [Cited by in F6Publishing: 16] [Article Influence: 9.4] [Reference Citation Analysis]
13 Cao B, Park C, Subramaniapillai M, Lee Y, Iacobucci M, Mansur RB, Zuckerman H, Phan L, McIntyre RS. The Efficacy of Vortioxetine on Anhedonia in Patients With Major Depressive Disorder. Front Psychiatry 2019;10:17. [PMID: 30766492 DOI: 10.3389/fpsyt.2019.00017] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
14 Caraci F, Leggio GM, Salomone S, Drago F. New drugs in psychiatry: focus on new pharmacological targets. F1000Res 2017;6:397. [PMID: 28408985 DOI: 10.12688/f1000research.10233.1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
15 Vicent-Gil M, Raventós B, Marín-Martínez ED, González-Simarro S, Martínez-Arán A, Bonnin CDM, Trujols J, Pérez-Blanco J, de Diego-Adeliño J, Puigdemont D, Serra-Blasco M, Cardoner N, Portella MJ. Testing the efficacy of INtegral Cognitive REMediation (INCREM) in major depressive disorder: study protocol for a randomized clinical trial. BMC Psychiatry 2019;19:135. [PMID: 31060604 DOI: 10.1186/s12888-019-2117-4] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Segura-Garcia C, Rania M, Carbone EA, de Filippis R, Aloi M, Caroleo M, Grasso G, Calabrò G, Fazia G, Staltari FA, Falvo A, Pugliese V, Gaetano R, Steardo L Jr, De Fazio P. Naturalistic and Uncontrolled Pilot Study on the Efficacy of Vortioxetine in Binge Eating Disorder With Comorbid Depression. Front Psychiatry 2021;12:635502. [PMID: 33815170 DOI: 10.3389/fpsyt.2021.635502] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
17 Wesnes KA, Gommoll C, Chen C, Sambunaris A, McIntyre RS, Harvey PD. Effects of levomilnacipran extended-release on major depressive disorder patients with cognitive impairments: post-hoc analysis of a phase III study. Int Clin Psychopharmacol 2017;32:72-9. [PMID: 27861191 DOI: 10.1097/YIC.0000000000000157] [Cited by in Crossref: 8] [Article Influence: 2.0] [Reference Citation Analysis]
18 Chin CN, Zain A, Hemrungrojn S, Ung EK, Kwansanit P, Au Yong KC, Chong MSW, Inpa C, Yen TH, Yeoh BBD, Tay LK, Bernardo C, Lim LC, Yap CH, Fones C, Nayak A, Nelleman L. Results of a real-world study on vortioxetine in patients with major depressive disorder in South East Asia (REVIDA). Curr Med Res Opin 2018;34:1975-84. [PMID: 29768955 DOI: 10.1080/03007995.2018.1477746] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
19 Mills NT, Sampson E, Fourrier C, Baune BT. Clinical Switching Strategies of Various Antidepressants to Vortioxetine in the PREDDICT Trial. Int J Neuropsychopharmacol 2021;24:314-21. [PMID: 33269395 DOI: 10.1093/ijnp/pyaa092] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Felice D, Guilloux JP, Pehrson A, Li Y, Mendez-David I, Gardier AM, Sanchez C, David DJ. Vortioxetine Improves Context Discrimination in Mice Through a Neurogenesis Independent Mechanism. Front Pharmacol 2018;9:204. [PMID: 29593535 DOI: 10.3389/fphar.2018.00204] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
21 Hupalo S, Bryce CA, Bangasser DA, Berridge CW, Valentino RJ, Floresco SB. Corticotropin-Releasing Factor (CRF) circuit modulation of cognition and motivation. Neurosci Biobehav Rev 2019;103:50-9. [PMID: 31212019 DOI: 10.1016/j.neubiorev.2019.06.010] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 9.5] [Reference Citation Analysis]
22 Riga MS, Teruel-martí V, Sánchez C, Celada P, Artigas F. Subchronic vortioxetine treatment –but not escitalopram– enhances pyramidal neuron activity in the rat prefrontal cortex. Neuropharmacology 2017;113:148-55. [DOI: 10.1016/j.neuropharm.2016.09.024] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
23 Zhang MW, Ho RC. Controversies of the Effect of Ketamine on Cognition. Front Psychiatry 2016;7:47. [PMID: 27065891 DOI: 10.3389/fpsyt.2016.00047] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
24 Riga MS, Sanchez C, Celada P, Artigas F. Sub-chronic vortioxetine (but not escitalopram) normalizes brain rhythm alterations and memory deficits induced by serotonin depletion in rats. Neuropharmacology 2020;178:108238. [DOI: 10.1016/j.neuropharm.2020.108238] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Peyrovian B, Rosenblat JD, Pan Z, Iacobucci M, Brietzke E, Mcintyre RS. The glycine site of NMDA receptors: A target for cognitive enhancement in psychiatric disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2019;92:387-404. [DOI: 10.1016/j.pnpbp.2019.02.001] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 13.5] [Reference Citation Analysis]